Form 4: Alpha Tau Medical CFO Trades Shares

Alpha Tau Medical Ltd. Chief Financial Officer, Raphi Levy, reported transactions involving the acquisition and disposition of ordinary shares.

Summary

• Raphi Levy, Chief Financial Officer of Alpha Tau Medical Ltd., reported a transaction on July 2, 2026.
• Levy acquired 17,873 ordinary shares at a price of $2.98 per share.
• Following this acquisition, Levy disposed of 17,873 ordinary shares at a price of $13.0027 per share.
• The total number of ordinary shares beneficially owned by Levy after these transactions is 90,180.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction with a profitable outcome for the executive, but without additional context on the reasons for the sale.

Positives

• The disposal of shares occurred at a significantly higher price ($13.0027) than the acquisition price ($2.98), indicating a profitable transaction for the reporting person.
• The reporting person maintains a substantial beneficial ownership of 90,180 ordinary shares after the reported transactions.

Negatives

• The disposal of a significant number of shares by a key executive could be interpreted negatively by the market, depending on the context and reasons for the sale.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported sale by a CFO at a profit is common, but the market will scrutinize the volume and timing in relation to company performance and future prospects.

Stakeholder Impact

• Shareholders may view the CFO's sale with caution, potentially questioning the executive's confidence in future stock performance, despite the profitable nature of the transaction.

Key Dates

Recommendation

The filing details a profitable insider sale, which is a common event. Without further information on the company's performance or the strategic reasons behind the sale, a 'hold' recommendation is prudent, balancing the positive aspect of the executive's profit against potential market concerns about insider selling.

Keywords

Alpha Tau Medical, Form 4, Insider Trading, Share Transaction, Raphi Levy, Chief Financial Officer, Ordinary Shares, SEC Filing